Diabetes
Do GLP-1 drugs show pancreatitis safety signals?
Open access · cc by · source: Europe PMC
Across 6,751 FAERS ICSRs (plus 39 case-series patients), AP reporting signals appeared for all studied GLP-1 RAs, especially exenatide and liraglutide.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
Scope note — pancreatitis case series ≠ T1D efficacy trial
Limits the claim's scope: a different population, assay, or outcome.
Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
Evidence for the claim as stated.
In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Scope note — spontaneous pancreatitis case series cannot estimate comparative mortality in T2D initiators
Limits the claim's scope: a different population, assay, or outcome.
FAERS biliary signals were clearer for DPP-4 inhibitors than for GLP-1 RAs as a class, with agent exceptions.
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
Scope note — pancreatitis ICSRs ≠ biliary-disorder RORs; both lack incidence denominators
Limits the claim's scope: a different population, assay, or outcome.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Evidence for the claim as stated.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on GLP-1 receptor agonists
Among 2,215 biliary FAERS reports, DPP-4 inhibitors had ROR 3.09 (sitagliptin 3.46). Overall GLP-1 RAs were called non-significant (ROR 1.60), but semaglutide (4.06) and liraglutide (3.88) signaled; serious outcomes were 76.88% of DPP-4 vs 51.55% of GLP-1 reports.
Placed as a scope qualifier on GLP-1 receptor agonists
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Placed as supporting evidence on GLP-1 receptor agonists
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Study at a glance
- Design
- Other — Case series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP
- N
- N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events
- Population
- FAERS reports and case-series patients with AP while on GLP-1 RAs
- Outcome
- Disproportionality signals for acute pancreatitis across GLP-1 RA agents
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Do GLP-1 drugs show pancreatitis safety signals?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Case series of 39 AP patients.
Our case series comprised thirty-nine patients who experienced AP events while on GLP-1 RAs.
6,751 FAERS ICSRs retrieved.
Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs.
Key findings
Median age 57; 98.3% of FAERS cases serious. AP signals across agents, with emphasis on exenatide and liraglutide.
Methodology
Reviewed AP case reports and mined FAERS (2005–2023) with ROR/PRR/BCPNN/MGPS for seven GLP-1 RAs including tirzepatide.
Limitations
Spontaneous reporting signals are not incidence rates or proof of causality vs confounding by indication.
Related papers in this topic
Same topic cluster — not a recommendation engine.